Rhenman & Partners Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-220,000	Closed	-$3.36M	–	89
2018 Q2	$3.36M	Sell	220,000 -50,000	-19%	-$892K	0.34%	67
2018 Q1	$6.07M	Sell	270,000 -68,882	-20%	-$1.91M	0.75%	51
2017 Q4	$10.2M	Buy	+338,882	New	+$10.8M	1.38%	27
2017 Q3	–	Sell	-30,000	Closed	-$837K	–	95
2017 Q2	$837K	Sell	30,000 -60,000	-67%	-$1.79M	0.12%	84
2017 Q1	$3.09M	Buy	90,000 +20,000	+29%	+$706K	0.49%	69
2016 Q4	$2.02M	Buy	70,000 +20,000	+40%	+$529K	0.39%	74
2016 Q3	$1.59M	Hold	50,000	–	–	0.25%	85
2016 Q2	$1.62M	Hold	50,000	–	–	0.29%	81
2016 Q1	$1.4M	Sell	50,000 -70,000	-58%	-$1.53M	0.28%	81
2015 Q4	$4.28M	Sell	120,000 -76,000	-39%	-$2.68M	0.65%	55
2015 Q3	$6.48M	Buy	196,000 +5,000	+3%	+$208K	1.03%	41
2015 Q2	$8M	Buy	191,000 +20,000	+12%	+$774K	0.96%	32
2015 Q1	$5.57M	Buy	171,000 +6,000	+4%	+$206K	0.94%	37
2014 Q4	$5.24M	Sell	165,000 -54,000	-25%	-$1.53M	1.52%	21
2014 Q3	$5.42M	Sell	219,000 -11,000	-5%	-$257K	1.59%	17
2014 Q2	$5.2M	Buy	230,000 +53,117	+30%	+$1.11M	1.54%	16
2014 Q1	$4.3M	Buy	176,883 +91,883	+108%	+$2.32M	1.29%	23
2013 Q4	$2.12M	Buy	+85,000	New	+$2.01M	0.83%	55

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Rhenman & Partners Asset Management's ACAD Position: Q3 2018 in Review

Rhenman & Partners Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 220,000 shares — an estimated $3.36M sold.

Rhenman & Partners Asset Management first reported a position in ACAD in Q4 2013 and held it in 18 quarters. The position peaked at $10.2M in Q4 2017. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

Rhenman & Partners Asset Management reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Rhenman & Partners Asset Management sold 220,000 Acadia Pharmaceuticals shares in Q3 2018, an estimated $3.36M.
Rhenman & Partners Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 18 quarters.
Rhenman & Partners Asset Management's Acadia Pharmaceuticals position peaked at $10.2M in Q4 2017.
184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2018, filed 3 Oct 2018.